Development of humanized antibodies as cancer therapeutics (Q40431510)

20 September 2017

Development of humanized antibodies as cancer therapeutics (English)

1 reference

20 September 2017

Zhengxing Qu

1

1 reference

20 September 2017

Gary L Griffiths

2

1 reference

20 September 2017

William A Wegener

3

1 reference

20 September 2017

Chien-Hsing Chang

4

1 reference

20 September 2017

Serengulam V Govindan

5

1 reference

20 September 2017

Ivan D Horak

6

1 reference

20 September 2017

Hans J Hansen

7

1 reference

20 September 2017

David M Goldenberg

8

1 reference

20 September 2017

1 May 2005

1 reference

20 September 2017

1 reference

20 September 2017

36

1 reference

20 September 2017

84-95

1 reference

20 September 2017

1

1 reference

The coming of age of cancer radioimmunoconjugates

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Signaling antibodies in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

A clinical and scientific overview of tositumomab and iodine I 131 tositumomab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Renaissance of cancer therapeutic antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

"Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Cloning immunoglobulin variable domains for expression by the polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Complete variable region sequence of a nonfunctionally rearranged kappa light chain transcribed in the nonsecretor P3-X63-Ag8.653 myeloma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Reshaping human antibodies: grafting an antilysozyme activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Modeling antibody hypervariable loops: a combined algorithm.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

High-level expression of chimeric antibodies using adapted cDNA variable region cassettes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Quantitative analysis of cell surface HLA structures by means of monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing D-amino acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2005.01.008

10.1016/J.YMETH.2005.01.008

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference